Multiple myeloma: open trials in Germany

64 open trials have a site in Germany. Registry data; only the trial team decides who can take part.

NCT05583617
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Trial Treatment · Phase 1/2 · Hoffmann-La Roche
University Medical Center Hamburg-Eppendorf, Hamburg · Universitaet Leipzig, Leipzig
Registry updated 2026-11-05
NCT07825064
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 2 · Hoffmann-La Roche
HELIOS Klinikum Berlin Buch GmbH, Berlin · Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsklinikum Bonn AöR, Bonn · Klinikum Chemnitz gGmbH, Chemnitz · Universitaetsklinikum Koeln AöR, Cologne · Technische Universitaet Dresden, Dresden · Universitaetsklinikum Erlangen AöR, Erlangen · Universitaetsklinikum Essen (AoR), Essen · Universitaetsmedizin Greifswald KöR, Greifswald · University Medical Center Hamburg-Eppendorf, Hamburg · Medizinische Hochschule Hannover, Hanover · Universitaetsklinikum Heidelberg AöR, Heidelberg · Universitaetsklinikum Jena KöR, Jena · Universitaetsklinikum Schleswig-Holstein AöR, Kiel · Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Munich · Klinikum Nuernberg, Nuremberg · Klinikum Oldenburg Aor, Oldenburg · Universitaetsklinikum Regensburg AöR, Regensburg · Universitaetsklinikum Ulm AoR, Ulm · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-11-05
NCT06189833
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS
Trial Treatment · Phase 2 · European Myeloma Network B.V.
University Medical Center Hamburg-Eppendorf, Hamburg · Klinikum rechts der Isar der TU Muenchen AöR, Munich
Registry updated 2026-11-04
NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Technische Universitaet Dresden, Dresden · Gemeinschaftspraxis Haematologie Onkologie, Dresden · University Medical Center Hamburg-Eppendorf, Hamburg · Universitaetsklinikum Schleswig-Holstein AöR, Luebeck · Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Mainz · Kliniken Ostalb gemeinnuetzige kommunale Anstalt des oeffentlichen Rechts, Mutlangen · Universitaetsklinikum Regensburg AöR, Regensburg · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-11-04
NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
University Medical Center Hamburg-Eppendorf, Hamburg · Universitaetsklinikum Heidelberg AöR, Heidelberg · Klinikum Oldenburg Aor, Oldenburg
Registry updated 2026-11-04
NCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsklinikum Heidelberg AöR, Heidelberg · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-11-03
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
HELIOS Klinikum Berlin Buch GmbH, Berlin · Universitaetsklinikum Essen (AoR), Essen · Martin-Luther-Universitaet Halle-Wittenberg, Halle (Saale) · University Medical Center Hamburg-Eppendorf, Hamburg · Klinikum Nuernberg, Nuremberg · Universitaetsklinikum Tuebingen AöR, Tuebingen · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-11-03
NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Marien Hospital Duesseldorf GmbH, Duesseldorf · Universitaetsklinikum Heidelberg AöR, Heidelberg · Universitaetsklinikum Jena KöR, Jena · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-11-03
NCT07665450
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
St. Barbara-Klinik Hamm GmbH, Hamm · Universitaetsklinikum Wuerzburg, Würzburg
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Universitätsklinikum Aachen, Aachen · Sozialstiftung Bamberg, Bamberg · Universitätsklinikum Bonn, Bonn · Gemeinschaftspraxis Hämatologie - Onkologie Freiberg-Richter, Jacobasch, Illmer, Wolf, Dresden · Marien Hospital Düsseldorf, Düsseldorf · Erfurt · Universitaetsklinikum Hamburg-Eppendorf, Hamburg · Asklepios Altona, Hamburg · Praxis Onkologie am Raschplatz, Hanover · Universitaetsklinikum Schleswig Holstein Campus Kiel, Kiel · Universitaetsklinik Marburg, Marburg · TUM Klinikum, München · Klinikum Traunstein, Traunstein · Universitaetsklinikum Tuebingen, Tübingen · Medizinisches Versorgungszentrum, Weiden · Gemeinschaftspraxis Dres. med. Björn Schöttker & Dominik Pretscher, Würzburg
Registry updated 2026-10-30
NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Trial Treatment · Phase 1/2 · AstraZeneca
Essen · Freiburg im Breisgau · Hamburg · Heidelberg · Lübeck · Nuremberg · Tübingen · Würzburg
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Charite Universitaetsmedizin Berlin KöR, Berlin · Klinikum Chemnitz gGmbH, Chemnitz · University Medical Center Hamburg-Eppendorf, Hamburg · Medizinische Hochschule Hannover, Hanover · Universitaetsklinikum Heidelberg AöR, Heidelberg · Universitaetsklinikum Schleswig-Holstein AöR, Kiel · Universitaet Leipzig, Leipzig · Otto Von Guericke Universitaet Magdeburg, Magdeburg · Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Munich · Klinikum Nuernberg, Nuremberg · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Universitaetsklinikum Aachen AöR, Aachen · Staedtisches Klinikum Braunschweig gGmbH, Brunswick · Klinikum Chemnitz gGmbH, Chemnitz · Medical Center- University of Freiburg, Freiburg im Breisgau · Asklepios Kliniken Hamburg GmbH, Hamburg · Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR, Mainz · Universitaetsklinikum Regensburg AöR, Regensburg · Universitaetsklinikum Tuebingen AöR, Tuebingen · Universitaetsklinikum Ulm AoR, Ulm
Registry updated 2026-10-27
NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie
University Medical Center Hamburg-Eppendorf, Hamburg · Universitaetsklinikum Heidelberg AöR, Heidelberg · LMU Klinikum Muenchen AöR, Munich · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-10-27
NCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1/2 · Regeneron Pharmaceuticals
Universitätsklinikum Essen, Essen · Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR, Mainz · Universitätsklinikum Würzburg, Würzburg
Registry updated 2026-10-26
NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Trial Treatment · Phase 1/2 · BeOne Medicines
Universitaetsklinikum Aachen AöR, Aachen · Technische Universität Dresden, Dresden · University Medical Center Hamburg-Eppendorf, Hamburg · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-10-26
NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Trial Treatment · Phase 3 · AstraZeneca
Berlin · Dresden · Essen · Freiburg im Breisgau · Hamburg · Leipzig · München · Oldenburg
Registry updated 2026-10-21
2025-523815-12-00
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Cilag International
Universitaetsklinikum Bonn AöR, Bonn · Medical Center- University of Freiburg, Freiburg im Breisgau · University Medical Center Hamburg-Eppendorf, Hamburg · Asklepios Kliniken Hamburg GmbH, Hamburg · Medizinische Hochschule Hannover, Hanover · Universitaet Leipzig, Leipzig · Universitaetsklinikum Tuebingen AöR, Tuebingen
Registry updated 2026-10-19
2026-526654-14-01
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Trial Treatment · Phase 3 · Janssen Cilag International
Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsmedizin Greifswald KöR, Greifswald · St. Barbara-Klinik Hamm GmbH, Hamm · LMU Klinikum Muenchen AöR, Munich · Universitaetsklinikum Tuebingen AöR, Tuebingen · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-10-14
NCT07648264
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Trial Treatment · Phase 3 · CSL Behring
Universitaetsklinikum Giessen und Marburg GmbH Standort Giessen, Giessen · Universitaetsmedizin der Johannes Gutenberg - Universitaet Mainz, Mainz
Registry updated 2026-10-14
NCT04643002
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Trial Treatment · Phase 1/2 · Sanofi
Frankfurt · Lübeck
Registry updated 2026-10-13
NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Trial Treatment · Phase 3 · Takeda
University Hospital Cologne AöR, Cologne · Universitaetsklinikum Essen (AoR), Essen · Asklepios Kliniken Hamburg GmbH, Hamburg
Registry updated 2026-10-13
NCT07555938
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial Treatment · Phase 3 · Hoffmann-La Roche
Universitaetsklinikum Augsburg, Augsburg · HELIOS Klinikum Bad Saarow GmbH, Bad Saarow · Vivantes Netzwerk fuer Gesundheit GmbH, Berlin · Charite Universitaetsmedizin Berlin KöR, Berlin · Universitaetsklinikum Bonn AöR, Bonn · Universitaetsklinikum Duesseldorf AöR, Duesseldorf · Marien Hospital Duesseldorf GmbH, Duesseldorf · Goethe University Frankfurt, Frankfurt Am Main · Universitaetsmedizin Greifswald KöR, Greifswald · Asklepios Kliniken Hamburg GmbH, Hamburg · St. Barbara-Klinik Hamm GmbH, Hamm · Klinikum Region Hannover GmbH, Hanover · Universitaetsklinikum Schleswig-Holstein AöR, Kiel · Universitaetsklinikum Tuebingen AöR, Tuebingen · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-10-13
2026-525367-40-00
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
Trial Treatment · Phase 3 · AstraZeneca AB
Charite Universitaetsmedizin Berlin KöR, Berlin · Technische Universitaet Dresden, Dresden · Universitaetsklinikum Essen (AoR), Essen · University Medical Center Hamburg-Eppendorf, Hamburg · Universitaet Leipzig, Leipzig · Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Munich · Klinikum Oldenburg Aor, Oldenburg
Registry updated 2026-10-12
NCT05243797
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Trial Treatment · Phase 3 · European Myeloma Network B.V.
University Medical Center Hamburg-Eppendorf, Hamburg · Universitaetsklinikum Heidelberg AöR, Heidelberg · Universitaetsklinikum Jena KöR, Jena · Universitaetsklinikum Schleswig-Holstein AöR, Luebeck · Klinikum rechts der Isar der TU Muenchen AöR, Munich · Klinikum Nuernberg, Nuremberg · Universitaetsklinikum Tuebingen AöR, Tuebingen · Universitaetsklinikum Wuerzburg AöR, Wuerzburg
Registry updated 2026-10-07

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error